We are pleased to introduce the collection of Model Organisms in Renal Pharmacology.
Model organisms are non-human species that are used in the lab environment to help scientists understand biological processes. Model organisms represent an invaluable resource for fundamental and applied research, allowing prediction studies, modeling, and the identification of action mechanisms. This article collection will showcase studies of Model Organisms from bacteria, yeast, viruses, eukaryotes, and any others that have significance to the field of renal pharmacology as a whole. Kidney disease is a worldwide threat with 697.5 million individuals recorded to have been affected by chronic kidney disease in 2017 (Lancet, 2020:395:709-733). Therefore, the use of model organisms aids in using non-human but biological relevant alternatives to help us better understand and treat these diseases.
Classically used for biomedical studies, model organisms are progressively entering many disciplines within pharmacology. Drug development requires tests on model organisms before approval of new drugs can be tested on humans. This makes studies obtained using model organisms are essential for progress within the field. We aim to acknowledge the use of model organisms and the research carried out to determine the best model organisms within the field.
This Research Topic welcomes original research, reviews, mini-reviews, perspectives manuscripts within, but not limited to, the following areas:
• Analysis of the most appropriate model organisms in renal pharmacology research to determine new potential pharmaceuticals in the treatment of renal disease.
• Studies using model organisms for research in the nephrology areas looking at the reno-protective effects of treatment.
• Studies using model organisms with renin-angiotensin system blockers in both diabetic and non-diabetic backgrounds.
• Comparative studies of different organisms to study different treatments of renal diseases for example analysis of non-specific and toxic immunosuppressive regimes in comparison to more specific interventions.
• The use of model organisms to study renal transplantation, immunosuppressants, and nephrotoxicity.
• The use of model organisms in determining mechanisms of drug action and the assessment of interactions between drugs and targets within a renal disease background.
• Studies using the model organisms to understand the mechanism of acute or chronic kidney damage in infections (viral, bacterial etc.) and autoimmune diseases.
• Studies using model organisms to study renal pharmacological agents derived from natural resources (plants, microbes, and marine products).
Please note: Manuscripts submitted to the section must fall within the scope of the section. Please refer to the authors notes.
We are pleased to introduce the collection of Model Organisms in Renal Pharmacology.
Model organisms are non-human species that are used in the lab environment to help scientists understand biological processes. Model organisms represent an invaluable resource for fundamental and applied research, allowing prediction studies, modeling, and the identification of action mechanisms. This article collection will showcase studies of Model Organisms from bacteria, yeast, viruses, eukaryotes, and any others that have significance to the field of renal pharmacology as a whole. Kidney disease is a worldwide threat with 697.5 million individuals recorded to have been affected by chronic kidney disease in 2017 (Lancet, 2020:395:709-733). Therefore, the use of model organisms aids in using non-human but biological relevant alternatives to help us better understand and treat these diseases.
Classically used for biomedical studies, model organisms are progressively entering many disciplines within pharmacology. Drug development requires tests on model organisms before approval of new drugs can be tested on humans. This makes studies obtained using model organisms are essential for progress within the field. We aim to acknowledge the use of model organisms and the research carried out to determine the best model organisms within the field.
This Research Topic welcomes original research, reviews, mini-reviews, perspectives manuscripts within, but not limited to, the following areas:
• Analysis of the most appropriate model organisms in renal pharmacology research to determine new potential pharmaceuticals in the treatment of renal disease.
• Studies using model organisms for research in the nephrology areas looking at the reno-protective effects of treatment.
• Studies using model organisms with renin-angiotensin system blockers in both diabetic and non-diabetic backgrounds.
• Comparative studies of different organisms to study different treatments of renal diseases for example analysis of non-specific and toxic immunosuppressive regimes in comparison to more specific interventions.
• The use of model organisms to study renal transplantation, immunosuppressants, and nephrotoxicity.
• The use of model organisms in determining mechanisms of drug action and the assessment of interactions between drugs and targets within a renal disease background.
• Studies using the model organisms to understand the mechanism of acute or chronic kidney damage in infections (viral, bacterial etc.) and autoimmune diseases.
• Studies using model organisms to study renal pharmacological agents derived from natural resources (plants, microbes, and marine products).
Please note: Manuscripts submitted to the section must fall within the scope of the section. Please refer to the authors notes.
